Nationwide quality assessment of treatment for chronic obstructive pulmonary disease.
Background
Chronic obstructive pulmonary disease (COPD) requires careful ambulatory care. If treatment is effective, exacerbation and hospitalization can be preventable. Appropriate management is important; the disease prevalence is high, as is the demand on healthcare resources. Here, we have reported the results of nationwide quality assessment performed with the aims of improving patient management, reducing progression to severe status, and minimizing medical care expenses.


Methods
The Health Insurance Review and Assessment Service (HIRA) engaged in quality assessment three times from May 2014 to April 2017. Medical care institutions were evaluated in terms of the pulmonary function test (PFT), patient revisit, and inhaled bronchodilator prescription rates.


Results
The numbers of patients assessed were 141,782, 142,790, and 143,339 in years 1, 2, and 3, respectively; the numbers of medical care institutions assessed were 6,691, 6,722, and 6,470, respectively. The PFT implementation rates were 58.7%, 62.5%, and 67.9% for years 1, 2, and 3, respectively; these rates were highest for tertiary hospitals, followed by general and local hospitals, as well as primary healthcare clinics. The repeat visit rates were 85.5%, 92.1%, and 85.0% for years 1, 2, and 3, respectively; these rates were highest for general hospitals, followed by local and tertiary hospitals, and primary healthcare clinics. The inhaled bronchodilator prescription rates were 67.9%, 71.2%, and 76.9% for years 1, 2, and 3, respectively; these rates increased with increasing hospital grade.


Conclusions
The PFT and inhaled bronchodilator prescription rates improved over the 3-year nationwide quality assessment period.
['Kim|Kyu Yean|KY|', 'Yoo|Kwang Ha|KH|', 'Choi|Hye Sook|HS|', 'Kim|Bo Yeon|BY|', 'Ahn|Sang In|SI|', 'Jo|Yon U|YU|', 'Rhee|Chin Kook|CK|']
quality assessment Chronic obstructive pulmonary disease (COPD)